BioCentury | Aug 7, 2006
Strategy

Life after amylin

...Thousand Oaks, Calif.). In the same period, the company also acquired chemical ligation technology from Gryphon...
...limits to the size of peptides that can be made this way. This is where Gryphon's...
...created with Gryphon technology, but the concept allows us to think about how to use Gryphon's...
BioCentury | May 1, 2006
Company News

SciClone management update

...director; Hired: Friedhelm Blobel as president, CEO and a director, formerly president and CEO of Gryphon Therapeutics Inc. WIR...
BioCentury | Apr 25, 2006
Company News

SciClone names Blobel CEO

...June 2. He was most recently president, CEO and a director of protein therapeutics company Gryphon...
BioCentury | Mar 6, 2006
Company News

Amgen, Amylin, Gryphon Sciences Inc. deal

...on the call that it had acquired the chemical ligation technology and associated IP from Gryphon...
...not disclosed. Amgen Inc. (AMGN), Thousand Oaks, Calif. Amylin Pharmaceuticals Inc. (AMLN), San Diego, Calif. Gryphon...
BioCentury | Sep 29, 2003
Finance

Ebb & Flow

...administration. In addition to CERA, ROCZ has a play on synthetic erythropoiesis protein (SEP) from Gryphon...
BioCentury | Jul 28, 2003
Product Development

Roche's product deal flow

...Ph III for ovarian cancer. 3/25/02 Gryphon Hematology Preclinical Received an exclusive global license to Gryphon's...
BioCentury | Feb 10, 2003
Company News

Gryphon Sciences Inc. other research news

...Roche (SWX:ROCZ, Basel, Switzerland) has an exclusive license to SEP (see BioCentury, April 22, 2002). Gryphon...
BioCentury | Sep 30, 2002
Company News

Gryphon Sciences Inc. board of directors update

Gryphon Sciences Inc. , South San Francisco, Calif. Business: Chemistry Appointed: Patrick Zenner, retired president and CEO of the North American subsidiary of Roche WIR Staff...
BioCentury | Jul 15, 2002
Finance

Ebb & Flow

...by HealthCare Ventures; Advent Venture Partners; and Merrill Lynch Ventures. Other investors included Prolog Ventures; Gryphon...
BioCentury | Jul 11, 2002
Financial News

MetaPhore raises $30 million

...HealthCare Ventures VI; Advent Venture Partners; and Merrill Lynch Ventures. Other investors included Prolog Ventures; Gryphon...
Items per page:
1 - 10 of 43
BioCentury | Aug 7, 2006
Strategy

Life after amylin

...Thousand Oaks, Calif.). In the same period, the company also acquired chemical ligation technology from Gryphon...
...limits to the size of peptides that can be made this way. This is where Gryphon's...
...created with Gryphon technology, but the concept allows us to think about how to use Gryphon's...
BioCentury | May 1, 2006
Company News

SciClone management update

...director; Hired: Friedhelm Blobel as president, CEO and a director, formerly president and CEO of Gryphon Therapeutics Inc. WIR...
BioCentury | Apr 25, 2006
Company News

SciClone names Blobel CEO

...June 2. He was most recently president, CEO and a director of protein therapeutics company Gryphon...
BioCentury | Mar 6, 2006
Company News

Amgen, Amylin, Gryphon Sciences Inc. deal

...on the call that it had acquired the chemical ligation technology and associated IP from Gryphon...
...not disclosed. Amgen Inc. (AMGN), Thousand Oaks, Calif. Amylin Pharmaceuticals Inc. (AMLN), San Diego, Calif. Gryphon...
BioCentury | Sep 29, 2003
Finance

Ebb & Flow

...administration. In addition to CERA, ROCZ has a play on synthetic erythropoiesis protein (SEP) from Gryphon...
BioCentury | Jul 28, 2003
Product Development

Roche's product deal flow

...Ph III for ovarian cancer. 3/25/02 Gryphon Hematology Preclinical Received an exclusive global license to Gryphon's...
BioCentury | Feb 10, 2003
Company News

Gryphon Sciences Inc. other research news

...Roche (SWX:ROCZ, Basel, Switzerland) has an exclusive license to SEP (see BioCentury, April 22, 2002). Gryphon...
BioCentury | Sep 30, 2002
Company News

Gryphon Sciences Inc. board of directors update

Gryphon Sciences Inc. , South San Francisco, Calif. Business: Chemistry Appointed: Patrick Zenner, retired president and CEO of the North American subsidiary of Roche WIR Staff...
BioCentury | Jul 15, 2002
Finance

Ebb & Flow

...by HealthCare Ventures; Advent Venture Partners; and Merrill Lynch Ventures. Other investors included Prolog Ventures; Gryphon...
BioCentury | Jul 11, 2002
Financial News

MetaPhore raises $30 million

...HealthCare Ventures VI; Advent Venture Partners; and Merrill Lynch Ventures. Other investors included Prolog Ventures; Gryphon...
Items per page:
1 - 10 of 43